Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.

FEVERTREE DRINKS PLC (FEVR)     

dreamcatcher - 08 Nov 2014 16:51



Fever-Tree is the world's leading supplier of premium carbonated mixers for alcoholic spirits by retail sales value, with distribution to approximately 50 countries internationally.

Based in the UK, the brand was launched in 2005 by Charles Rolls and Tim Warrillow to provide high quality, natural mixers which could accompany the growing demand for premium spirits. The Group now sells a range of 12 differentiated flavours to hotels, restaurants, bars and cafes ("On Trade") as well as supermarkets and off-licenses for retail purchase ("Off Trade"). Approximately 70 per cent. of the Group's sales were derived from outside of the UK in FY13 with the key overseas markets being the US, Spain, and Belgium.

The Group's mixers are designed to be accompaniments for alcoholic spirits or used in cocktails, although they can also be consumed on their own. Since 2005, the Company has launched at least one new product a year, which includes 4 variants of tonic water, 2 variants of ginger beer, 3 variants of lemonade, and one variant each of ginger ale, soda water and cola.

7 November 2014
Admission to AIM and first day of dealings


http://www.fever-tree.com/

Chart.aspx?Provider=EODIntra&Code=FEVR&SChart.aspx?Provider=EODIntra&Code=FEVR&SFlag Counter

dreamcatcher - 12 Dec 2017 16:30 - 561 of 711

From the sains, morr, tes, write up -


“Alcohol sales are up by nearly £172mln compared to this time last year and while volume sales have increased, this impressive growth is mainly a result of consumers choosing more expensive festive tipples," said Fraser McKevit, head of retail and consumer insight at Kantar.
“Gin, whisky and sparkling wine all saw significant growth: up by 26%, 10% and 7% respectively as shoppers pushed the boat out.”

bermon - 19 Dec 2017 11:06 - 562 of 711

Forget Bitcoin bubble - will Fevertree go pop?

LONDON, Dec 19 (Reuters) - A carbonated drinks manufacturer is always in bubble territory.

But after a 1,450 percent share price rise since a late-2014 market debut, arguably none is looking as frothy as upmarket tonic water and mixers maker Fevertree Drinks.

Its shares have started to deflate, but only against a backdrop of general angst over asset valuations, with global equities and bonds at or close to record peaks and cryptocurrency Bitcoin up almost 20-fold this year alone.

A move by Schweppes to compete in the premium drinks segment is behind some of the recent weakness, but fund managers do not expect this to have any sizeable impact on Fevertree's growth.

Nor do they see any let-up in what has become the Fevertree standard - beating analysts' earnings forecasts.

Richard Watts, who runs the 3.2 billion pound ($4.3 billion)Old Mutual UK Mid Cap Fund and is the biggest institutional shareholder of Fevertree, topped up his holdings in the company in the last 4-5 weeks.

"We think there are significant amounts of upside left in the shares," he said.

He said Fevertree's sales momentum is exceptionally strong as its mixers are stocked in more UK locations in the on-trade (e.g. bars, restaurants) and off-trade (e.g. supermarkets, shops), and gain more shelf space at retailers.

Britain is Fevertree's largest market. RBC Capital Markets put its contribution to the company's organic revenue growth at more than 50 percent since 2015, accelerating to more than 60 percent since the second half of 2016.

This performance, helped by a premium gin boom, shows no sign of abating. UK sales increased more than 100 percent in the first half of 2017 - and against a robust prior year level.

Watts said the international business is growing at a very healthy clip, too.

Fevertree is beefing up its overseas presence. It recently opened a U.S. office and appointed a CEO for its business there.

The brand name Fever-Tree is the colloquial name for the cinchona tree, the bark of which produces quinine - a key ingredient in tonic water.

Even after such a stellar run, Fevertree gets consistent forecast upgrades from the analysts that cover the stock.

Fevertree's most recent trading update predicted 2017 results materially ahead of market expectations, prompting house broker Investec to lift its revenue forecast by 6 percent.

Investec started 2016 and 2017 with earnings per share (EPS) forecasts about 70 percent below what they ultimately became, assuming no further changes for the 2017 estimate.

COKE FIGHTS BACK

Forecasts might be unchallenging, but early-stage companies like Fevertree are inherently riskier investments than more established companies with a longer earnings history.

Fevertree is listed on the FTSE AIM index, the London Stock Exchange's market for growing companies, which has less stringent regulations than the main market.

"This company (Fevertree) is growing quickly and there's always uncertainty when that happens - and things can go wrong. I think it's right for the analysts to be prudent in their forecasts," said Aberdeen Standard Investments' Harry Nimmo.

"But I don't think it needs much stretch of the imagination to predict that the forecasts should be beaten," he said.

Fevertree is held across a wide range of funds at Aberdeen Standard Investments, where Nimmo is head of smaller companies.

With a market capitalisation of 2.3 billion pounds, Fevertree is hardly a small company any more, said Nimmo. As such, some of ASI's large/midcap funds have been buying more of its shares, while portfolios of smaller stocks have sold some.

Coca-Cola's relaunch of Schweppes in the UK has been a cause for concern among Fevertree investors, particularly given it comprises premium mixer range, Schweppes 1783, and has a big marketing spend behind it.

Fevertree's shares have fallen about 7 percent since early October, when the announcement was made.

Both Nimmo or Watts are relatively unfazed. Watts said if anything, the impact will be temporary.

cynic - 19 Dec 2017 11:11 - 563 of 711

investors piling in today, and any bears must be getting very singed ........ hohoho :-)

cynic - 19 Jan 2018 08:45 - 564 of 711

hohoho! ...... i've been telling you all to buy this one for ages and ages, but few followed
now t/o seriously in the offing and currently up just a measly £2.00 though has been higher

skinny - 19 Jan 2018 10:17 - 565 of 711

soapbox1.gif

:-)

HARRYCAT - 19 Jan 2018 12:10 - 566 of 711

Morgan Stanley for you:
"With high growth potential and attractive returns, we see Fever-Tree as a unique opportunity in European Staples. Our channel checking and proprietary industry model suggest the premium mixers market could triple in the next 5 years with Fever-Tree well placed to capitalise on this growth.

Fever-Tree's performance to date has been impressive. The company effectively created the premium mixers category, giving consumers more choice and a higher quality product, with better cash margins for the on-trade and a high rate of sales in the retail channel. Drawing on our extensive channel checking, we expect the premiumisation of mixers to continue and see Fever-Tree as well placed to capitalise on this growth despite increased competition.

The penetration of premium mixers is currently 9% of the total mixers market versus 33% for premium spirits, the closest proxy for mixers. Our industry model assumes further penetration of premium mixers, driving a ~20% CAGR 2017-25 across Fever-Tree's core markets. This growth underpins our forecasts for 23% revenue CAGR, 20% EBITDA CAGR and 20% EPS CAGR between FY17-20

Fever-Tree employs an asset light business model. It does not own its manufacturing and relies on third parties for distribution. The group thus has impressive returns on invested capital, which we estimate to grow sustainably going forward from 43% in FY16 to 63% by FY20, while FCF should double.

We think the growth potential for Fever-Tree is underappreciated (particularly by sell-side consensus), and we view Fever-Tree's asset light, high returns business model favourably. We set our £30.00 price target based on our DCF methodology, with the risk reward skewed to the upside, in our view. Increased competition or a slower penetration of premium mixer than we are currently expecting are key risks to our rating and price target."

midknight - 19 Jan 2018 12:20 - 567 of 711

Telegraph

skinny - 19 Jan 2018 12:24 - 568 of 711

19 Jan 18 Jefferies International Buy 2,455.50 - 3000.00 Initiates/Starts

skinny - 24 Jan 2018 07:06 - 569 of 711

Trading Update


Fever-Tree, the world's leading supplier of premium carbonated mixers, is pleased to announce its trading update for the year ended 31 December 2017.

The Company has delivered another period of very strong growth with full year revenue expected to be circa £169 million, reflecting growth of 66% on 2016 with sales in the second half expected to be ahead of the prior year period by 58%.

The performance in the UK in the second half of 2017 has once again been exceptionally strong. The Company gained significant market share from its competitors culminating in Fever-Tree ending the year as the number one mixer brand by value in the UK off-trade channel. (IRI - Total UK Retail Mixer Market value share - 13 weeks to 31/12/17).

Full year revenue in the UK is expected to be circa 96% ahead of 2016. The Group's performance over the Christmas period was particularly notable with impressive rate of sales growth across all channels, formats and flavours. The growth of the mixer category continues to accelerate, driven by Fever-Tree's unwavering focus on quality and supported by the on-going premiumisation of the wider spirits sector.

Sales in Continental Europe performed well in the second half of 2017, and it is anticipated that full year revenue will be circa 42% ahead of 2016.

In the USA, strong revenue growth also continued during the second half of 2017, and as a result, full year revenue for the territory is expected to be circa 39% ahead of 2016. The establishment of a North American office and the appointment of Charles Gibb as North American CEO, announced in December 2017, were significant milestones and reflect the Group's ambition and commitment to the North American market.

Rest of World sales growth accelerated in the second half of 2017 and full year revenue is expected to be circa 57% ahead of 2016.

In view of the Company's very strong sales performance in the final two months of the year, the Group took the opportunity to bring forward planned operational expenditure in the US to invest ahead of growth. Year-end net cash position is anticipated to be in line with Board expectations with significant cash balances still to collect given the strength of trading over the Christmas period.

FY17 expectations

Reflecting the continued strong performance through to the end of the year, the Board expects that the outcome for the full year will be comfortably ahead of market expectations.

Fever-Tree will announce its Preliminary Results on 13th March 2018.

Commenting on today's announcement, Tim Warrillow, Co-founder and CEO of Fever-Tree said:

"I am very proud of our performance in 2017 which has seen Fever-Tree end the year as the number one mixer brand at UK retail. Our pioneering approach and commitment to providing consumers with the highest quality range of mixers continues to capture peoples' imagination and is transforming the wider UK mixer category which as a result is now the fastest growing category across the soft drinks sector.

While we have seen strong growth across all regions, our performance in the UK over the Christmas period was once again exceptional. Our growing range of mixers and formats are appealing not only to our loyal customers but also bringing consumers back to the category and importantly attracting a new younger audience.

There is clear evidence that the same trends of premiumisation and mixability that we've previously highlighted are accelerating and we are increasingly excited by the global opportunity this presents particularly as we transition to our own operations in the US."



dreamcatcher - 24 Jan 2018 19:25 - 570 of 711

Fever-Tree dampens Unilever talk and toasts sales jump

The Evening Standard


Sales at Fever-Tree soared in 2017
Posh mixers maker Fever-Tree on Wednesday sought to play down talks of a takeover by Unilever as it revealed another year of “exceptional” sales growth.
Boss Tim Warrillow declined to comment on City rumours that consumer goods giant Unilever is set to swoop for the business. But he told the Standard that the company “can never say it is not open to talks” from a suitor.
He stressed: “Our focus right now is on further growth”.


The AIM-listed firm said 2017 revenues are expected to be up 66% to £169 million.
It was boosted by sales in the UK surging 96%, thanks to larger orders from supermarkets and more pubs stocking Fever-Tree tonics.
Read more
Fever-Tree proves just the tonic the Square Mile needs
Mixers maker Fever-Tree to beat full-year forecasts
Fever-tree keeps on bubbling as its profits double
Warrillow was upbeat about 2018, but added: “It would be unrealistic to think we can keep growing in the UK at this pace.”

Nicola Mallard, an analyst at Investec, said Fever-Tree “has continued to gain share from the competition”. She pointed out that the firm has overtaken Schweppes and is now the number one mixer brand (by value) in the UK off-trade.
Fever-Tree shares rose 98.46p to 2533.46p. They floated at 134p in November 2014

cynic - 02 Feb 2018 10:40 - 571 of 711

continuing to tick up though on unexciting volume
perhaps an indication of a lack of shares on offer (available), especially as it is a "proper" stock and not MM-only

cynic - 02 Mar 2018 15:41 - 572 of 711

as we draw to the end of another dreadful week, i thought to draw attention to this one yet again
though the figures are not due for another 2/3 weeks, sp has stayed firm despite the non-appearance of the much touted t/o offer
volume is not especially strong, but i thought it interesting nevertheless

dreamcatcher - 03 Mar 2018 07:23 - 573 of 711

Good news/takeover = £30 + ?

cynic - 03 Mar 2018 08:06 - 574 of 711

you wish on both counts :-)

dreamcatcher - 03 Mar 2018 14:02 - 575 of 711

Good luck if you hold Cynic.

cynic - 03 Mar 2018 16:25 - 576 of 711

i do and now at zero cost

dreamcatcher - 13 Mar 2018 08:12 - 577 of 711

Preliminary results

Financial highlights:

· Revenue up 66% to £170.2m (2016: £102.2m)
· Gross profit margin of 53.5% (2016: 55.2%)
· Adjusted EBITDA* of £58.7m (2016: £35.8m)
· Robust balance sheet with net cash at year end of £50.9m (2016: £26.9m)
· Diluted EPS of 39.15 pence (2016: 23.70 pence)
· Final dividend of 7.64 pence per share recommended to shareholders, bringing total dividend to 10.65 pence per share (2016: 6.25 pence per share)

* Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation, share based payment charges and finance costs.

Operational highlights:

· Continued strong growth across all regions, channels, flavours and formats with the UK once again delivering an exceptional performance
· Ended 2017 as the number one mixer brand by value in the UK off-trade channel1
· Further new distribution wins globally across both On and Off Trade channels; new listings, and increased stores and product ranging within existing customers;
· Establishment of wholly owned North American operation and appointment of North American CEO
· Continued focus on innovation with appointment of Innovation Director and successful launch of Limited Edition Clementine Tonic in UK over the Christmas period
· Named the no.1 best-selling and no.1 trending tonic water in Drinks International's survey of world's top 250 bars for the fourth year running

cynic - 13 Mar 2018 08:17 - 578 of 711

just about beat forecasts and forward statement is quite bullish
sp has held up quite well for the moment (down 80), but some of the steam may evaporate in the coming weeks
that said, there remains the mooted bid in the background

dreamcatcher - 13 Mar 2018 14:18 - 579 of 711

Investors not impressed.

cynic - 13 Mar 2018 14:44 - 580 of 711

i sold 50% of my trading shares yesterdayat 2740 and bought them back again this morning at 2534
that was certainly not the bottom, but so far so good
Register now or login to post to this thread.